Abstract
Concurrent epidemics of respiratory viruses provide avenues for intricate virus-virus interactions, yet how molecular-level viral interactions patterns shape viral ecology and epidemic dynamics remain enigmatic. Here, we present real-world virus crosstalk by comprehensively analyzing diagnostic data from a large cohort (37,415 respiratory illness cases pre-COVID-19 pandemic, 22,239 cases thereafter), mainly infants/toddlers, sourced from the same local hospital. Such high-risk group cohort allowed us to examine consistent coinfections among 7 respiratory viruses, despite under an overall reduced infection rates due to COVID-19 disruption. We explored drivers of stable ecosystem and identified a directional virus-virus interaction network between influenza and other respiratory viruses. Monthly prevalence patterns analysis of individual virus revealed IAV positively interacted with RSV, characterized by synchronous seasonality (ρ= 0.67). Conversely, IAV negatively interacted with HPIV3, marked by asynchronous seasonality (ρ= -0.56). Sequential/simultaneous coinfection experiments further confirmed two viruses could contact in the same cell but show distinct coinfection outcomes, such as IAV significantly augmented RSV infection but inhibited HPIV3. We further demonstrated coinfection with IAV and RSV led to exacerbated lung damage in mice, while were associated with aggravated disease outcomes among children. Post-COVID-19, we observed a notable suppression in the spread of respiratory viruses, with a particularly sharp decline in influenza. This reduced influenza activity disrupted virus interactions between influenza and other respiratory viruses, driving the concurrent resurgence of other respiratory viruses. When influenza gradually returns to circulation, the interactions could be reinstated, shaping respiratory virus circulations in a predictable and typical pattern. These findings underscore the pivotal role of influenza in directional interplays among respiratory viruses that shape viral ecology.
The respiratory viral ecology with directional virus-virus interactions. A substantial cohort of infants and toddlers, comprising 37,415 cases of acute respiratory infection (ARI) pre-COVID-19 pandemic and 22,239 cases thereafter, underwent testing for seven human respiratory viruses: ADV, RSV, IAV, IBV, HPIV1, 2, and 3. The prevalence of coinfection with at least two viruses was 11.18% (pre-) and 9.70% (post-) respectively, showcasing a stable and intricate ecosystem of multiple respiratory viruses even amidst the global disruption caused by COVID-19. Findings from experimental coinfections are consistent with viral seasonal dynamics, where positive interactions (red arrows), such as Flu promoting RSV, exhibit synchronous seasonal patterns, whereas negative interactions (blue arrows), like Flu inhibiting HPIV, display asynchronous seasonal trends. Viruses that demonstrate no interactions with each other (gray arrows), like ADV and RSV, can coexist harmoniously within the host environment (accommodate).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Key R&D Program (2023YFC2307802,2022YFB3605001), the National Natural Science Foundation of China (82272307, 82341056, 82302495), the Hubei Province Natural Science Foundation (2023BCB087, 2022CFA047, 2022CFB624, 2021BAB117), Knowledge Innovation Program of Wuhan (2022020801010116), the Fundamental Research Funds for the Central Universities (2042024kf1026), China Postdoctoral Science Foundation (2023M742709, 2023M732697, BX20230276), and Postdoctoral Innovative Research Foundation of Hubei Province (326870). We are also grateful to a special fund for Large-scale Instrument and Equipment Sharing Foundation of Wuhan University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Medical Ethical Committee of the Maternal and Child Health Hospital of Hubei Province (2021-IEC-XM042), which waived the requirement for informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.